Risen (Suzhou) Pharma Tech

Risen Pharma is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics for autoimmune and inflammatory diseases. The company focuses on high-value targets within the JAK/STAT and IRAK signaling pathways to address significant unmet medical needs in dermatology and rheumatology. Its lead programs include RS1805, a dual JAK1/TYK2 inhibitor, and RS101, an IRAK4 inhibitor, both of which have progressed into clinical trials. Risen Pharma leverages its internal R&D capabilities to build a robust pipeline of candidates aimed at providing safer and more effective treatments for chronic inflammatory conditions.